Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Länsförsäkringar Skåne’s real estate company Länshem Skåne in connection with an acquisition from Wihlborgs
Mandate

Vinge advises Länsförsäkringar Skåne’s real estate company Länshem Skåne in connection with an acquisition from Wihlborgs

August 23, 2019 M&A

Vinge has advised Länsförsäkringar Skåne’s real estate company Länshem Skåne in connection with the acquisition from Wihlborgs of the property Gängtappen 1 i Dockan in Malmö for SEK 720 million.

Gängtappen was built in 1958 as a head office for Kockums and has a lettable area of 14,400 square metres and is fully rented. Länsförsäkringar Skåne is the largest tenant. Completion will occur on 1 December 2019. 

Vinge’s team consisted of Henrik Ossborn together with, among others, associates Fredrik Christiansson, Jessica Salomonsson and Jack Bengtsson. Mathias Lindquist provided environmental law advice.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026